Fred Alger Management, LLC Mirati Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

$19.8 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $1.13 Million - $1.68 Million	26,977 New	26,977 $1.58 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $4.03 Million - $8.02 Million	-53,150 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $7.02 Million - $10.1 Million	53,150 New	53,150 $7.8 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $971,551 - $1.3 Million	-7,353 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $45,216 - $56,435	-314 Reduced 4.1%	7,353 $1.19 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $1.37 Million - $1.9 Million	-8,596 Reduced 52.86%	7,667 $1.31 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $792,424 - $1.17 Million	4,890 Added 43.0%	16,263 $3.57 Million
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $608,545 - $898,741	5,373 Added 89.55%	11,373 $1.89 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $216,030 - $361,170	-3,000 Reduced 33.33%	6,000 $685,000
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $244,230 - $406,735	-3,500 Reduced 28.0%	9,000 $692,000
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $35,380 - $64,430	500 Added 4.17%	12,500 $1.61 Million
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $545,370 - $767,200	7,000 Added 140.0%	12,000 $935,000
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $59,490 - $104,710	-1,000 Reduced 16.67%	5,000 $515,000
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $261,900 - $473,700	6,000 New	6,000 $440,000
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $320,000 - $474,300	-10,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $94,200 - $125,400	2,000 Added 25.0%	10,000 $471,000
Q2 2018 Jul 19, 2018	BUY	$26.05 - $52.4 $208,400 - $419,200	8,000 New	8,000 $394,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Account